C07K 14/4756
Neuregulins, i.e. p185erbb2 ligands, glial growth factor, heregulin, aria, neu differentiation factor
Official title: {Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor}
C07K14/4756 (Neuregulins, i.e. p185erbb2 ligands, glial growth factor, heregulin, aria, neu differentiation factor) appears on 164 US grants and 211 published applications in this corpus.
Search patents in C07K- Granted patents
- 164
- Published applications
- 211
- Assignees
- 97
- Inventors
- 335
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 3 | 0 |
| 1997 | 9 | 0 |
| 1998 | 7 | 0 |
| 1999 | 11 | 0 |
| 2000 | 9 | 0 |
| 2001 | 6 | 1 |
| 2002 | 5 | 11 |
| 2003 | 4 | 18 |
| 2004 | 6 | 11 |
| 2005 | 4 | 11 |
| 2006 | 8 | 11 |
| 2007 | 4 | 10 |
| 2008 | 5 | 11 |
| 2009 | 11 | 8 |
| 2010 | 10 | 7 |
| 2011 | 5 | 10 |
| 2012 | 6 | 6 |
| 2013 | 3 | 6 |
| 2014 | 5 | 11 |
| 2015 | 6 | 9 |
| 2016 | 3 | 11 |
| 2017 | 4 | 5 |
| 2018 | 4 | 4 |
| 2019 | 4 | 7 |
| 2020 | 4 | 8 |
| 2021 | 3 | 6 |
| 2022 | 2 | 8 |
| 2023 | 1 | 4 |
| 2024 | 4 | 6 |
| 2025 | 5 | 7 |
| 2026 | 2 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for treating heart failure18 Aug 2026US 12,708,658 B2Zensun (Shanghai) Science & Technology, Co., Ltd.
- Recombinant human neuregulin derivatives and use thereof9 Jun 2026US 12,649,769 B2Zensun (Shanghai) Science & Technology, Co., Ltd.
- Method and kit for treating a neurodegenerative disease11 Nov 2025US 12,466,865 B2The Board of Trustees of the University of Illinois
- GDNF fusion polypeptides and methods of use thereof2 Sep 2025US 12,404,313 B2Keros Therapeutics, Inc.
- Methods for promoting wound healing and hair growth comprising GDNF administration15 Jul 2025US 12,357,674 B2The Jackson Laboratory
- Method of obtaining recombinant human brain-derived neurotrophic factor6 Aug 2026US 2026/0226122 A1Dompé Farmaceutici S.P.A.
- Gdnf mimetic peptide amphiphiles9 Jul 2026US 2026/0192016 A1Northwestern University
- Methods and devices for promoting nerve growth and regeneration29 Jan 2026US 2026/0027184 A1
- Gdnf fusion polypeptides and methods of use thereof22 Jan 2026US 2026/0022150 A1Keros Therapeutics, Inc.
- Methods for promoting wound healing and hair growth comprising gdnf administration4 Dec 2025US 2025/0367256 A9The Jackson Laboratory
Most cited
By later US patents
- Use of NRG4, or inhibitors thereof, in the treatment of colon and pancreatic cancers133US 7,198,899 B2Chiron Corporation · 2007
- Use of NRG4, or inhibitors thereof, in the treatment of colon and pancreatic cancers133US 7,476,506 B2Novartis Vaccines and Diagnostics, Inc. · 2009
- Structure, production and use of heregulin98US 5,367,060 AGenentech, Inc. · 1994
- Method for purifying heregulin87US 5,641,869 AGenentech, Inc. · 1997
- DNA encoding glial mitogenic factors68US 5,530,109 ACambridge NeuroScience, Inc. · 1996